Home » Archive by Category

News

San Diego biotech news from BioSpace, Xconomy, PR Newswire, Marketwired and other sources, click on headlines to read the full story.

Polaris Group Announces Treatment Of First Patient In Phase 1 Study Of ADI-PEG 20 Plus Pemetrexed And Cisplatin In Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma

November 19, 2014 – 5:00 pm | Edit Post

SAN DIEGO, Nov. 20, 2014 /PRNewswire/ — Polaris Group announced today that the first patient has been dosed in its Phase 1 trial of ADI-PEG 20 in combination with pemetrexed and cisplatin for the treatment of malignant pleural mesothelioma (MPM) and non-squamous non-small cell lung carcinoma. Polaris Group is…

Batu Biologics Recruits Cancer Immunologist To Scientific Advisory Board

November 19, 2014 – 5:00 pm | Edit Post

SAN DIEGO–(BUSINESS WIRE)–Batu Biologics, an immunotherapy company working to develop ValloVax, an anti-angiogenic cancer vaccine, announced today the addition of Dr. Deyu Fang to its Scientific Advisory Board. Deyu Fang, Ph.D. is an immunologist and associate professor working in the Department of Pathology at Northwestern University Feinberg School of Medicine. Help employers find you…

ViaCyte, Inc. (Formerly Known as Novocell, Inc.) To Present At 26th Annual Piper Jaffray Healthcare Conference

November 19, 2014 – 5:00 pm | Edit Post

SAN DIEGO, Nov. 20, 2014 /PRNewswire/ — ViaCyte, Inc., a privately-held regenerative medicine company developing a stem cell-derived islet replacement therapy for the treatment of diabetes, today announced that Dr. Paul Laikind, President and Chief Executive Officer, will present…

Neothetics Prices IPO

November 19, 2014 – 5:00 pm | Edit Post

Neothetics Prices Initial Public Offering SAN DIEGO, Nov. 19, 2014 (GLOBE NEWSWIRE) — Neothetics, Inc. (Nasdaq:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market, today announced the pricing of its initial public…

OncoSec Medical Inc. And University of Washington Enter Sponsored Research Agreement

November 19, 2014 – 5:00 pm | Edit Post

SAN DIEGO–(BUSINESS WIRE)–OncoSec Medical Inc. (OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, has entered a Sponsored Research Agreement (SRA) with the University of Washington to evaluate the immunologic mechanisms of intratumoral DNA IL-12 electroporation. Help employers find you! Check out all the

Vital Therapies, Inc. (VTI) Expands Management Team

November 19, 2014 – 5:00 pm | Edit Post

SAN DIEGO, Nov. 20, 2014 (GLOBE NEWSWIRE) — Vital Therapies, Inc. (Nasdaq: VTL), a biotherapeutic company developing ELAD, a cell-based therapy targeting treatment of acute liver failure, announced the addition of John Dunn as General Counsel, reporting to Terry Winters, Ph.D., the Company’s Chief…

Otonomy, Inc. To Present At The Piper Jaffray Healthcare Conference

November 19, 2014 – 5:00 pm | Edit Post

SAN DIEGO, Nov. 20, 2014 (GLOBE NEWSWIRE) — Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the inner and middle ear, today announced that David A. Weber, Ph.D., president…

Salk scientists unveil powerful method to speed cancer drug discovery

November 19, 2014 – 5:00 pm | Edit Post

LA JOLLA–For decades, researchers have struggled to translate basic scientific discoveries about cancer into therapeutics that effectively–and with minimal side effects–shrink a tumor.

Taxus Cardium Reports On Third Quarter 2014 Results And Corporate Development Activities

November 19, 2014 – 5:00 pm | Edit Post

SAN DIEGO, Nov. 20, 2014 /PRNewswire/ –Taxus Cardium Pharmaceuticals Group Inc. (Trading Symbol: CRXM) and its advanced regenerative medicine business units today reported results for the third quarter ended September 30, 2014 and corporate development activities.

BioNano Genomics Raises $53 Million

November 19, 2014 – 4:01 pm | Edit Post

San Diego company sells genome mapping instruments that go beyond sequence.